Built for ministries, partners, and operators. If your question isn't answered below, convene with us directly.
GenREY is a physician-scientist-led regenerative biotechnology platform focused on translating breakthrough science into scalable clinical, commercial, and societal impact. The platform spans regenerative medicine, precision therapeutics, rare-disease intelligence, advanced drug delivery, novel drug development, tissue engineering, longevity and antiaging medicine, and translational biotechnology infrastructure.
GenREY is built as a platform, not a single-product company. Rather than relying on one technology or therapeutic area, GenREY develops multiple strategically aligned programs that share scientific infrastructure, intellectual property, translational expertise, and commercialization pathways, pursuing long-term innovation across several high-value areas while maintaining one unified scientific and operational foundation.
Our long-term vision is to help build a globally connected regenerative biotechnology ecosystem capable of translating scientific discovery into real-world healthcare solutions. We believe biotechnology will be one of the defining industries of the 21st century. GenREY is positioned to connect science, medicine, artificial intelligence, infrastructure, investment, and global health access into one coordinated platform.
Current focus areas include hair regeneration, precision drug delivery, rare disease intelligence, regenerative women's health, liver and organ biology, longevity and healthy aging, tissue engineering, novel drug development, and translational biotechnology infrastructure. These programs operate within a broader platform model where scientific knowledge, clinical pathways, and commercialization strategy support multiple areas of development.
iREY is GenREY's flagship regenerative hair platform and one of the first major programs within the broader GenREY ecosystem. It represents GenREY's approach to combining regenerative science, translational medicine, product development, and commercial deployment within a focused therapeutic and aesthetic category.
GenREY is headquartered in the United States, with its scientific and translational activities anchored in Houston and an administrative headquarters in Riyadh. The company is developing a long-term international strategy focused on GCC collaboration, including Saudi Arabia and other key Middle Eastern innovation hubs.
Our goal is not to operate within a single geography, but to build a bridge connecting world-class science, investment, and healthcare innovation across regions, and to support regional biotechnology capacity-building over time.
The GCC is one of the most important emerging centers for healthcare transformation, biotechnology investment, and national innovation. GenREY sees the region as strategic because of its commitment to science, healthcare modernization, sovereign investment, research capacity, and future-facing infrastructure development.
GenREY is designed around a blended funding model that may include grants, strategic partnerships, translational collaborations, institutional support, licensing opportunities, and long-term investment capital. Funding is aligned with platform development and scientific milestones rather than a single program.
GenREY is open to strategic partnerships that support scientific development, clinical translation, commercialization, and biotechnology infrastructure. Opportunities may include research collaborations, clinical programs, licensing, manufacturing partnerships, data initiatives, strategic investment, institutional partnerships, and regional capacity-building projects.
GenREY collaborates with scientists, physicians, research institutions, healthcare systems, universities, ministries, sovereign stakeholders, investors, strategic partners, and biotechnology innovators. We seek relationships that combine scientific seriousness, institutional credibility, execution capacity, and long-term impact.
Both. At the company level, GenREY is developing biotechnology programs, partnerships, intellectual property, and commercialization pathways. At the platform level, GenREY is creating an operating system for regenerative innovation that can support multiple programs across research, clinical development, manufacturing, commercialization, and global access.
While healthcare and biotechnology remain GenREY's primary focus, we believe regenerative science can eventually contribute to broader environmental and conservation challenges. Long-term biodiversity and wildlife initiatives may become part of the company's philanthropic and impact mission. See the Biodiversity page for the future areas of interest.
Qualified partners, researchers, institutions, advisors, investors, and strategic collaborators may reach us through the contact page or email [email protected]. We welcome serious inquiries from individuals and organizations aligned with regenerative biotechnology, translational medicine, global health innovation, and long-term scientific impact.
For partnership inquiries, investor briefings, research collaborations, and senior hiring discussions. Start the conversation here.